

Janne Fuglsang Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6242461/publications.pdf>

Version: 2024-02-01

24
papers

554
citations

1039880

9
h-index

1058333

14
g-index

24
all docs

24
docs citations

24
times ranked

1063
citing authors

#	ARTICLE	IF	CITATIONS
1	A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project. BMC Infectious Diseases, 2022, 22, 202.	1.3	5
2	Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients. Journal of Internal Medicine, 2021, 290, 1264-1267.	2.7	28
3	Emergency department testing is feasible but ineffective to eliminate hepatitis C in Denmark. Infectious Diseases, 2021, 53, 930-941.	1.4	5
4	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. PLoS ONE, 2020, 15, e0238203.	1.1	20
5	Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. PLoS ONE, 2020, 15, e0243725.	1.1	7
6	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
7	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
8	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
9	Hepatitis C prevalence in Denmark in 2016—An updated estimate using multiple national registers. , 2020, 15, e0238203.		0
10	Title is missing!. , 2020, 15, e0243725.		0
11	Title is missing!. , 2020, 15, e0243725.		0
12	Title is missing!. , 2020, 15, e0243725.		0
13	Title is missing!. , 2020, 15, e0243725.		0
14	Title is missing!. , 2020, 15, e0243725.		0
15	Title is missing!. , 2020, 15, e0243725.		0
16	Incidence, prevalence and risk factors for hepatitis C in Danish prisons. PLoS ONE, 2019, 14, e0220297.	1.1	15
17	Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C. PLoS ONE, 2019, 14, e0212036.	1.1	15
18	Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study. Addiction, 2019, 114, 494-503.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. <i>Gastroenterology</i> , 2018, 154, 1369-1379.	0.6	170
20	PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 83-87.	0.6	19
21	Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx257.	0.4	9
22	Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. <i>Ultraschall in Der Medizin</i> , 2017, 38, 648-654.	0.8	42
23	Feasibility of transient elastography versus real-time two-dimensional shear wave elastography in difficult-to-scan patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1354-1359.	0.6	23
24	Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 123-133.	0.6	186